Archive

Past coronavirus surges in Europe have predicted what was to come in the United States, but experts say the trend is more a cause for caution than alarm. New York’s experience with the pandemic offers lessons to health experts.

Last July, Andrea Ogg stood outside a pharmacy in Castle Rock, Colorado, fully prepared to lie to get herself a Covid-19 vaccine.

California to delay school vaccine mandate pending full FDA approval.

A regular round-up of the latest coronavirus news, plus insight, features and interviews from New Scientist about the covid-19 pandemic

A regular round-up of the latest coronavirus news, plus insight, features and interviews from New Scientist about the covid-19 pandemic

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The New York governor’s exposure comes as the state battles yet another variant that is more transmissible than previous versions of the virus.

The government’s shift reflects a recognition that stringent pandemic measures were stifling economic activity and eroding the island’s international competitiveness.

An increase in monkeypox infections in 21 countries outside Africa, including 78 in the UK, has raised concerns that a significant outbreak is under way - but Pfizer's chief executive has offered reassurances that it is very unlikely to become a pandemic.

Pfizer and BioNTech reported positive clinical data for a Covid-19 booster in children younger than 5, results released ahead of a June FDA advisory committee meeting scheduled to discuss the use of that vaccine and Moderna’s in kids. In other Covid news this week, the CDC issued a health advisory for Pfizer’s antiviral Paxlovid and a respiratory failure drug for Covid-19 flunked its clinical trial.

Vaccine deliveries to U.S. states are contingent on the Food and Drug Administration authorizing pediatric doses, a step that could occur as soon as next week.

The much-anticipated review on Wednesday could clear the way for regulators to grant emergency authorization for coronavirus vaccines for American children as young as 6 months old.

The moves at a meeting on Wednesday could clear the way for regulators to grant emergency authorization for coronavirus vaccines for American children as young as 6 months old.

The moves at a meeting on Wednesday could clear the way for regulators to grant emergency authorization for coronavirus vaccines for American children as young as 6 months old.

Parents now must decide whether or not to vaccinate their children against COVID-19.

Dr. Anthony Fauci has confirmed that he is battling Covid-19 again after previously testing negative for the virus. Fauci is on his second course of Paxlovid.

Dr. Lisa Gwynn, a pediatrician with University of Miami Health System who had advocated for vaccine access for poor young kids, was removed from board.

How long should I wait after a third dose? Should I wait for an Omicron-specific vaccine? Your questions answered

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

BA.5, a new Omicron subvariant of the coronavirus, has become dominant, accounting for 65% of infections nationwide, according to the Centers for Disease Control and Prevention. Some experts have called it “the worst variant we have seen so far,” given its high transmissibility and its ability to evade immunity conferred by vaccination or prior infection.

Music, Film, TV and Political News Coverage

Megacaps Amazon (AMZN), Alphabet (GOOG)(GOOGL) and Microsoft (MSFT) highlight an exceptionally busy week of earnings releases. Coke (KO), GE (GE), Ford (F), McDonalds (MCD) are also on tap.

Oral antiviral Paxlovid saw stronger-than-expected sales in the first half of the year, but still hasn't captured the international markets.

This fall, Americans could get boosted with a mRNA Covid-19 vaccine unlike any that's come before. Some experts wonder whether the Omicron-specific boosters will come in time to make a difference.

Albert Bourla, CEO of drugmaker Pfizer, has tested positive for Covid-19 and has "very mild symptoms," he said in a tweet on Monday.

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

Moderna to sue BioNTech/Pfizer over COVID vaccine.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

The pending arrival of an Omicron booster shot marks an ambitious new phase in the nation's vaccination campaign before a possible new COVID surge.

The pending arrival of an Omicron booster shot marks an ambitious new phase in the nation's vaccination campaign before a possible new COVID surge.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.

Moderna is suing Pfizer and BioNTech for infringing patents related to mRNA technology; Paxlovid may not benefit adults 45 to 60; and more updates.